Oppenheimer analyst Jay Olson reiterated a Perform rating and $23.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) ahead of 1Q22 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE